Psoriasis: treatment with a new topical corticosteroid.
A total of 60 patients was treated for psoriasis in a double-blind, paired comparison study of 0.1% halcinonide with an active corticosteroid comparison drug as topical creams. An overall evaluation of comparative responses clearly demonstrated the superiority of halcinonide in a greater number of patients. Separate evaluation of the overall therapeutic responses also favored halcinonide, with a good to excellent response in 80% of patients compared to 65% with the control drug.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001624:Betamethasone Valerate / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D008875:Middle Aged; D011282:Pregnenediones / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D011282:Pregnenediones; D001624:Betamethasone Valerate